This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Original Articles

Changing the Course of Alzheimer’s Disease: Anti-Amyloid Disease-Modifying Treatments on the Horizon

Article Abstract

Objectives: To review the amyloid hypothesis as the predominant mechanistic theory of Alzheimer’s disease and update the status of new disease-modifying, anti-amyloid treatments in clinical development.

Data Sources: Governmental Web sites and those of professional Alzheimer’s disease associations and drug manufacturers were searched for new drugs in development. An English-language search of PubMed (January 2003-January 2006) was conducted using the search terms Alzheimer’s disease and amyloid hypothesis and each of the drugs and immunotherapies from the 4 identified classes of anti-amyloid, disease-modifying therapies.

Study Selection and Data Extraction: Studies and reports were selected on the basis of recent publication, adequate methodology, and completeness of data.

Data Synthesis: Immunotherapy, gamma-secretase inhibitors, selective neurotoxic aggregated 42-amino acid peptide subspecies of amyloid beta (Abeta42)-lowering agents (tarenflurbil), inhibitors of amyloid aggregation (tramiprosate), and statins show promise in clinical trials. Safety remains an important factor. Disease-modifying drugs that specifically target the amyloid cascade and do not interact with essential biological pathways are expected to possess a lower rate of unintended adverse events.

Agents that selectively target Abeta42 production (e.g., tarenflurbil), block Abeta aggregation (e.g., tramiprosate), or enhance alpha-secretase activity (statins) offer hope for disease modification and prevention and do not appear to interfere with other biological pathways.

Conclusions: Discovery of safe and effective disease-modifying therapies will usher in a new age of Alzheimer’s disease treatment.


Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Related Articles

Volume: 9

Quick Links: Dementia , Neurologic and Neurocognitive

References